Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Find trials that include:  Any drugs shown
Results 1-5 of 5 for your search:
Start Over
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP 01611, NCI-2014-01584, UPCC 01611, NCT01350401
Gene-Modified T cells in Treating Patients with Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 258514, NCI-2015-02080, NCT02650986
Gene and Vaccine Therapy in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 12-000153, NCI-2012-01548, NCT01697527
Laboratory Treated T-Cells in Treating Patients with NY-ESO-1 Expressing Metastatic or Locally Advanced Recurrent Solid Tumors or Malignant Meningioma
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 to 66
Trial IDs: 13-C-0214, NCI-2015-00137, 130214, 1308-1249, P131300, RD-13-VII-07, NCT01967823
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients with Locally Advanced or Metastatic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 16 and over
Trial IDs: 13-001624, NCI-2014-00221, 1311-1278, 208.13.0-h, CA184-346, NCT02070406
Start Over